{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:28:49Z","timestamp":1789140529314,"version":"build-2803163510"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Human leukocyte antigen G (HLA-G) is a potential checkpoint molecule that plays a key role in cervical carcinogenesis. The purpose of this study was to construct and validate a prognostic risk model to predict the overall survival (OS) of cervical cancer patients, providing a reference for individualized clinical treatment that may lead to better clinical outcomes. HLA-G-driven differentially expressed genes (DEGs) were obtained from two cervical carcinoma cell lines, namely, SiHa and HeLa, with stable overexpression of HLA-G by RNA sequencing (RNA-seq). The biological functions of these HLA-G-driven DEGs were analysed by GO enrichment and KEGG pathway using the \u201cclusterProfiler\u201d package. The protein-protein interactions (PPIs) were assessed using the STRING database. The prognostic relevance of each DEG was evaluated by univariate Cox regression using the TCGA-CESC dataset. After the TCGA-CESC cohort was randomly divided into training set and testing set, and a prognostic risk model was constructed by LASSO and stepwise multivariate Cox regression analysis in training set and validated in testing set or in different types of cervical cancer set. The predictive ability of the prognostic risk model or nomogram was evaluated by a series of bioinformatics methods. A total of 1108 candidate HLA-G-driven DEGs, including 391 upregulated and 717 downregulated genes, were obtained and were enriched mostly in the ErbB pathway, steroid biosynthesis, and MAPK pathway. Then, an HLA-G-driven DEG signature consisting of the eight most important prognostic genes <jats:italic>CD46, LGALS9, PGM1, SPRY4, CACNB3, PLIN2, MSMO1<\/jats:italic>, and <jats:italic>DAGLB<\/jats:italic> was identified as a key predictor of cervical cancer. Multivariate Cox regression analysis showed that this signature is an independent risk factor for the overall survival of CESC patients. Kaplan-Meier survival analysis showed that the 5-year overall survival rate is 23.0% and 84.6% for the high-risk and low-risk patients, respectively (<jats:italic>P<\/jats:italic>&amp;lt;0.001). The receiver operating characteristic (ROC) curve of this prognostic model with an area under the curve (AUC)\u00a0was 0.896 for 5 years, which was better than that of other clinical traits. This prognostic risk model was also successfully validated in different subtypes of cervical cancer, including the keratinizing squamous cell carcinoma, non-keratinizing squamous cell carcinoma, squamous cell neoplasms, non-squamous cell neoplasms set. Single-sample gene set enrichment (ssGSEA) algorithm and Tumor Immune Dysfunction and Exclusion (TIDE) analysis confirmed that this signature influence tumour microenvironment and immune checkpoint blockade. A nomogram that integrated risk score, age, clinical stage, histological grade, and pathological type was then built to predict the overall survival of CESC patients and evaluated by calibration curves, AUC, concordance index (C-index) and decision curve analysis (DCA). To summarize, we developed and validated a novel prognostic risk model for cervical cancer based on HLA-G-driven DEGs, and the prognostic signature showed great ability in predicting the overall survival of patients with cervical cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2022.851622","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T13:03:36Z","timestamp":1658149416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes"],"prefix":"10.3389","volume":"13","author":[{"given":"Hui-Hui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Jin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","unstructured":"World Health OrganizationCervical Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical Cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13027-018-0217-2","article-title":"Association of HLA-G 3' UTR Polymorphism and Expression With the Progression of Cervical Lesions in Human Papillomavirus 18 Infections","volume":"13","author":"Xu","year":"2018","journal-title":"Infect Agent Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01349","article-title":"The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.597468","article-title":"The Role of HLA-G in Tumor Escape: Manipulating the Phenotype and Function of Immune Cells","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.02.032","article-title":"A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1\/PD-L1, and HLA-G","volume":"68","author":"Carosella","year":"2015","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5604\/17322693.1220994","article-title":"PD1\/PD1L Pathway, HLA-G and T Regulatory Cells as New Markers of Immunosuppression in Cancers","volume":"70","author":"W\u0142asiuk","year":"2016","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0764","article-title":"CD8+PD-1-ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G","volume":"7","author":"Dumont","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1342023","article-title":"Intratumor Heterogeneity of Immune Checkpoints in Primary Renal Cell Cancer: Focus on HLA-G\/Ilt2\/Ilt4","volume":"6","author":"Rouas-Freiss","year":"2017","journal-title":"Oncoimmunology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900562","article-title":"Structural and Functional Basis for LILRB Immune Checkpoint Receptor Recognition of HLA-G Isoforms","volume":"203","author":"Kuroki","year":"2019","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G: An Immune Checkpoint Molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2012.07.041","article-title":"Human Leukocyte Antigen-G (HLA-G) Expression in Cervical Cancer Lesions is Associated With Disease Progression","volume":"73","author":"Li","year":"2012","journal-title":"Hum Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2010.01607.x","article-title":"Up-Regulation of HLA-G Expression in Cervical Premalignant and Malignant Lesions","volume":"77","author":"Zheng","year":"2011","journal-title":"Tissue Antigens"},{"key":"B16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijgo.2007.03.041","article-title":"Expression of Human Leukocyte Antigen-G and its Correlation With Interleukin-10 Expression in Cervical Carcinoma","volume":"98","author":"Yoon","year":"2007","journal-title":"Int J Gynaecol Obstet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000334089","article-title":"Altered HLA Class I and HLA-G Expression is Associated With IL-10 Expression in Patients With Cervical Cancer","volume":"79","author":"Rodr\u00edguez","year":"2012","journal-title":"Pathobiology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm356","article-title":"HLA-G Expression in Human Ovarian Carcinoma Counteracts NK Cell Function","volume":"18","author":"Lin","year":"2007","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/gigascience\/gix024","article-title":"A Reference Human Genome Dataset of the BGISEQ-500 Sequencer","volume":"6","author":"Huang","year":"2017","journal-title":"Gigascience"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the Added Predictive Ability of a New Marker: From Area Under the ROC Curve to Reclassification and Beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of Net Reclassification Improvement Calculations to Measure Usefulness of New Biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15270","article-title":"A five-mRNA Signature Associated With Post-Translational Modifications can Better Predict Recurrence and Survival in Cervical Cancer","volume":"24","author":"Ju","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4054","article-title":"Identification of a Novel Six-Gene Signature With Potential Prognostic and Therapeutic Value in Cervical Cancer","volume":"10","author":"Qu","year":"2021","journal-title":"Cancer Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.709493","article-title":"Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer","volume":"12","author":"Yu","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01444","article-title":"Development and Validation of an M6a RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma","volume":"10","author":"Pan","year":"2020","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12920-021-00885-3","article-title":"A Novel Prognostic Prediction Model Based on Seven Immune-Related RNAs for Predicting Overall Survival of Patients in Early Cervical Squamous Cell Carcinoma","volume":"14","author":"Qin","year":"2021","journal-title":"BMC Med Genomics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.625470","article-title":"Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma","volume":"8","author":"Zuo","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12935-021-02050-3","article-title":"Constructe a Novel 5 Hypoxia Genes Signature for Cervical Cancer","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.677831","article-title":"Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration","volume":"9","author":"Shang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.724172","article-title":"Identification of Biomarkers for Cervical Cancer Radiotherapy Resistance Based on RNA Sequencing Data","volume":"9","author":"Feng","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4748796","article-title":"Identification of Key Pathways and Establishment of a Seven-Gene Prognostic Signature in Cervical Cancer","volume":"2022","author":"An","year":"2022","journal-title":"J Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality Reduction for Visualizing Single-Cell Data Using UMAP","volume":"37","author":"Becht","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124528","article-title":"HLA-G: A New Immune Checkpoint in Cancer","volume":"21","author":"Krijgsman","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14514","article-title":"Expression of Classical Human Leukocyte Antigen Class I Antigens, HLA-E and HLA-G, is Adversely Prognostic in Pancreatic Cancer Patients","volume":"111","author":"Hiraoka","year":"2020","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00280.2019","article-title":"Extracellular Vesicles as Biomarkers and Therapeutic Targets for Cancer","volume":"318","author":"Urabe","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105131","article-title":"Lipid-Mediated Regulation of the Cancer-Immune Crosstalk","volume":"161","author":"Ma","year":"2020","journal-title":"Pharmacol Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/etm.2020.8454","article-title":"ERK\/MAPK Signalling Pathway and Tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp Ther Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2014.10.008","article-title":"The Role of Signaling Pathways in Cervical Cancer and Molecular Therapeutic Targets","volume":"45","author":"Manzo-Merino","year":"2014","journal-title":"Arch Med Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1911385116","article-title":"Whole-Exome Sequencing of Cervical Carcinomas Identifies Activating ERBB2 and PIK3CA Mutations as Targets for Combination Therapy","volume":"116","author":"Zammataro","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature21386","article-title":"Integrated Genomic and Molecular Characterization of Cervical Cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"eaah6163","DOI":"10.1126\/scisignal.aah6163","article-title":"TCR-Stimulated Changes in Cell Surface CD46 Expression Generate Type 1 Regulatory T Cells","volume":"10","author":"Ni Choileain","year":"2017","journal-title":"Sci Signal"},{"key":"B43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1385\/IR:32:1-3:031","article-title":"Atkinson JP. T-Cell Stimulation and Regulation: With Complements From CD46","volume":"32","author":"Kemper","year":"2005","journal-title":"Immunol Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129119","article-title":"Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer","volume":"10","author":"Punt","year":"2015","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2175927","article-title":"The Role of Galectins in Cervical Cancer Biology and Progression","volume":"2018","author":"Wang","year":"2018","journal-title":"BioMed Res Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.225","article-title":"Autoregulatory Loop Between TGF-\u03b21\/miR-411-5p\/SPRY4 and MAPK Pathway in Rhabdomyosarcoma Modulates Proliferation and Differentiation","volume":"6","author":"Sun","year":"2015","journal-title":"Cell Death Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.apsb.2016.11.001","article-title":"Targeting Calcium Signaling in Cancer Therapy","volume":"7","author":"Cui","year":"2017","journal-title":"Acta Pharm Sin B"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2006483","article-title":"Phosphoglucomutase 1 Inhibits Hepatocellular Carcinoma Progression by Regulating Glucose Trafficking","volume":"16","author":"Jin","year":"2018","journal-title":"PloS Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.tem.2016.09.001","article-title":"Perilipin 2 and Age-Related Metabolic Diseases: A New Perspective","volume":"27","author":"Conte","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.08.023","article-title":"Endogenous Sterol Metabolites Regulate Growth of EGFR\/KRAS-Dependent Tumors via LXR","volume":"12","author":"Gabitova","year":"2015","journal-title":"Cell Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nchembio.1105","article-title":"Dagl\u03b2 Inhibition Perturbs a Lipid Network Involved in Macrophage Inflammatory Responses","volume":"8","author":"Hsu","year":"2012","journal-title":"Nat Chem Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01074","article-title":"The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy","volume":"10","author":"Geller","year":"2019","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13048-020-00730-8","article-title":"Identification of an Autophagy-Related Gene Signature for Survival Prediction in Patients With Cervical Cancer","volume":"13","author":"Chen","year":"2020","journal-title":"J Ovarian Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040059","article-title":"CD46 and Oncologic Interactions: Friendly Fire Against Cancer","volume":"9","author":"Elvington","year":"2020","journal-title":"Antibod (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0433-3","article-title":"Looking Past PD-L1: Expression of Immune Checkpoint TIM-3 and its Ligand Galectin-9 in Cervical and Vulvar Squamous Neoplasia","volume":"33","author":"Curley","year":"2020","journal-title":"Mod Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7388","article-title":"Crosstalk Between Histone Modification and DNA Methylation Orchestrates the Epigenetic Regulation of the Costimulatory Factors, Tim-3 and Galectin-9, in Cervical Cancer","volume":"42","author":"Zhang","year":"2019","journal-title":"Oncol Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5905","article-title":"Long non-Coding RNAs on the Stage of Cervical Cancer (Review)","volume":"38","author":"Dong","year":"2017","journal-title":"Oncol Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.12102","article-title":"Upregulation of Long Noncoding RNA SPRY4-IT1 Correlates With Tumor Progression and Poor Prognosis in Cervical Cancer","volume":"6","author":"Cao","year":"2016","journal-title":"FEBS Open Bio"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00347","article-title":"and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Genet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12935-020-01380-y","article-title":"SUV39H1-DNMT3A-Mediated Epigenetic Regulation of Tim-3 and Galectin-9 in the Cervical Cancer","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1159\/000453195","article-title":"Lower Expression of SPRY4 Predicts a Poor Prognosis and Regulates Cell Proliferation in Colorectal Cancer","volume":"40","author":"Zhou","year":"2016","journal-title":"Cell Physiol Biochem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.851622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T13:03:39Z","timestamp":1658149419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.851622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2022.851622"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.851622","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"article-number":"851622"}}